Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

New Elite Feature: Find Similar Charts in Seconds

EyePoint, Inc.

Contributing Author

Recent Articles by EyePoint, Inc.

Sep-16	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT -5.74% GlobeNewswire
Sep-02	EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting EYPT GlobeNewswire
Aug-17	EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU 2.7mg in Wet AMD EYPT -66.98% GlobeNewswire
Aug-14	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT +9.42% GlobeNewswire
Aug-05	EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments EYPT GlobeNewswire
Jul-30	EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU for Treatment of Diabetic Macular Edema (DME) EYPT +7.89% GlobeNewswire
Jul-16	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT -5.85% GlobeNewswire
Jul-13	EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer EYPT GlobeNewswire
Jun-16	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT +6.62% GlobeNewswire
May-19	EyePoint Announces Participation at Upcoming Investor Conferences EYPT GlobeNewswire
May-18	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT -5.26% GlobeNewswire
May-14	EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU, Building Confidence Ahead of Mid-2026 Topline Data EYPT GlobeNewswire
May-06	EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments EYPT GlobeNewswire
Apr-29	EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 EYPT GlobeNewswire
Apr-16	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
Mar-16	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
Mar-04	EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments EYPT GlobeNewswire
Mar-02	EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU for the Treatment of Diabetic Macular Edema EYPT GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)